✦ LIBER ✦

A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)

✍ Scribed by Karen E. Bullock; William P. Petros; Islam Younis; Hope E. Uronis; Michael A. Morse; Gerard C. Blobe; S. Yousuf Zafar; Jon P. Gockerman; Joanne J. Lager; Roxanne Truax; Kellen L. Meadows; Leigh A. Howard; Margot M. O’Neill; Gloria Broadwater; Herbert I. Hurwitz; Johanna C. Bendell

Publisher: Springer
Year: 2010
Tongue: English
Weight: 265 KB
Volume: 67
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-010-1507-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of cetuximab, erlotinib, a

Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors

✍ Chia-Chi Lin; Emiliano Calvo; Kyriakos P. Papadopoulos; Amita Patnaik; John Sara 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 278 KB

Prednimustine in combination with methot

Prednimustine in combination with methotrexate and 5-fluorouracil in advanced breast cancer: A phase I–II study

✍ H. T. Mouridsen; E. Boesen 📂 Article 📅 1983 🏛 Springer US 🌐 English ⚖ 461 KB

Biomarker-based phase I dose-escalation,

Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer

✍ Karen Reckamp; Barbara Gitlitz; Lin-Chi Chen; Ravi Patel; Ginger Milne; Mary Syt 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 2 views

Phase I study of panobinostat in combina

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma

✍ J. Drappatz; E. Q. Lee; S. Hammond; S. A. Grimm; A. D. Norden; R. Beroukhim; M. 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 175 KB

Carboplatin and etoposide in advanced lu

Carboplatin and etoposide in advanced lung cancer: — a phase I study

✍ K. Liippo; V. Nikkanen; E. Heinonen 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 519 KB

Phase 1 trial of everolimus and gefitini

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer

✍ Daniel T. Milton; Gregory J. Riely; Christopher G. Azzoli; Jorge E. Gomez; Rober 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 3 views

## Abstract ## BACKGROUND. Preclinical studies have demonstrated that the inhibition of the PI3K/Akt/mTOR pathway restores gefitinib sensitivity in resistant cancer cell lines. A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dos